Coronavirus, Compulsory Licensing, and Collaboration: Analyzing the 2020 Global Vaccine Response with 20/20 Hindsight

In December 2019, COVID-19, a novel strain of the SARS-2 Virus, appeared in Wuhan, China. Within a year, over ninety million people had been infected, and two million had died. Amid all the death and desolation, humanity\u27s ingenuity and willpower emerged in history\u27s greatest vaccine race. The global community sought to find novel ways to protect innovation and intellectual property while still collaborating to roll out a vaccine in record time. Despite the presence of compulsory licensing provisions like 28 U.S.C. § 1498 and the Bayh-Dole Act in the U.S., and the TRIPS Agreement at the international level, the journey has been difficult. Thousands died while international players protected proprietary information and ensured that their countries\u27 citizens are first in line for the vaccine. Although dubbed a “once in a lifetime pandemic,” the COVID-19 outbreak provides a unique opportunity to contemplate ways to unify the world through intellectual property during a time of crisis, as well as a grim portent of what will become the new norm if we do not. This Article examines the impact and effectiveness of intellectual property licensing provisions worldwide to suggest improvements that might result in a quicker and more efficient response to future global health crises. By examining and learning from the plagues of the present, we might preserve the health of our future

THE POST-PANDEMIC ORDER: A BLUEPRINT FOR BALANCING HEALTH AND IP INTERESTS IN THE AGE OF COVID VARIANTS

In December 2021, the World Health Assembly (“WHA”) convened to develop a pandemic response treaty for future pandemics. Unfortunately, as presently envisioned, the resulting pandemic response framework will suffer from many of the same inadequacies that prevented existing frameworks from responding effectively to COVID-19. The threat of new pandemics emerging in the future—and new variants developing in the present—call for a more integrated, robust, comprehensive solution. This Article lays a blueprint for that solution: a global multilateral Council empowered to (1) investigate developing pandemics; (2) incentivize pharmaceutical companies to rapidly-produce vaccines and share them through voluntary licenses or TRIPS compulsory licensing provisions; (3) facilitate the rapid creation of raw material pipelines to vaccine and treatment developers; and (4) resolve related legal disputes to ensure a rapid and coordinated response to emerging diseases and variants

The Post-Pandemic Order: A Blueprint for Balancing Health and IP Interests in the Age of COVID Variants

In December 2021, the World Health Assembly (“WHA”) convened to develop a pandemic response treaty for future pandemics. Unfortunately, as presently envisioned, the resulting pandemic response framework will suffer from many of the same inadequacies that prevented existing frameworks from responding effectively to COVID-19. The threat of new pandemics emerging in the future—and new variants developing in the present—call for a more integrated, robust, comprehensive solution. This Article lays a blueprint for that solution: a global multilateral Council empowered to(1) investigate developing pandemics; (2) incentivize pharmaceutical companies to rapidly-produce vaccines and share them through voluntary licenses or TRIPS compulsory licensing provisions; (3) facilitate the rapid creation of raw material pipelines to vaccine and treatment developers; and (4) resolve related legal disputes to ensure a rapid and coordinated response to emerging diseases and variants

Distributionally robust optimization through the lens of submodularity

Distributionally robust optimization is used to solve decision making problems under adversarial uncertainty where the distribution of the uncertainty is itself ambiguous. In this paper, we identify a class of these instances that is solvable in polynomial time by viewing it through the lens of submodularity. We show that the sharpest upper bound on the expectation of the maximum of affine functions of a random vector is computable in polynomial time if each random variable is discrete with finite support and upper bounds (respectively lower bounds) on the expected values of a finite set of submodular (respectively supermodular) functions of the random vector are specified. This adds to known polynomial time solvable instances of the multimarginal optimal transport problem and the generalized moment problem by bridging ideas from convexity in continuous optimization to submodularity in discrete optimization. In turn, we show that a class of distributionally robust optimization problems with discrete random variables is solvable in polynomial time using the ellipsoid method. When the submodular (respectively supermodular) functions are structured, the sharp bound is computable by solving a compact linear program. We illustrate this in two cases. The first is a multimarginal optimal transport problem with given univariate marginal distributions and bivariate marginals satisfying specific positive dependence orders along with an extension to incorporate higher order marginal information. The second is a discrete moment problem where a set of marginal moments of the random variables are given along with lower bounds on the cross moments of pairs of random variables. Numerical experiments show that the bounds improve by 2 to 8 percent over bounds that use only univariate information in the first case, and by 8 to 15 percent over bounds that use the first moment in the second case.Comment: 36 Pages, 6 Figure

Clustering of Dust-Obscured Galaxies at z ~ 2

We present the angular autocorrelation function of 2603 dust-obscured galaxies (DOGs) in the Bootes field of the NOAO Deep Wide-Field Survey. DOGs are red, obscured galaxies, defined as having R-[24] \ge 14 (F_24/F_R \ga 1000). Spectroscopy indicates that they are located at 1.5 \la z \la 2.5. We find strong clustering, with r_0 = 7.40^{+1.27}_{-0.84} Mpc/h for the full F_24 > 0.3 mJy sample. The clustering and space density of the DOGs are consistent with those of submillimeter galaxies, suggestive of a connection between these populations. We find evidence for luminosity-dependent clustering, with the correlation length increasing to r_0 = 12.97^{+4.26}_{-2.64} Mpc/h for brighter (F_24 > 0.6 mJy) DOGs. Bright DOGs also reside in richer environments than fainter ones, suggesting these subsamples may not be drawn from the same parent population. The clustering amplitudes imply average halo masses of log M = 12.2^{+0.3}_{-0.2} Msun for the full DOG sample, rising to log M = 13.0^{+0.4}_{-0.3} Msun for brighter DOGs. In a biased structure formation scenario, the full DOG sample will, on average, evolve into ~ 3 L* present-day galaxies, whereas the most luminous DOGs may evolve into brightest cluster galaxies.Comment: ApJL in press; 4 pages, 3 figures, 1 tabl

Bronchiectasis in India:results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry

BACKGROUND: Bronchiectasis is a common but neglected chronic lung disease. Most epidemiological data are limited to cohorts from Europe and the USA, with few data from low-income and middle-income countries. We therefore aimed to describe the characteristics, severity of disease, microbiology, and treatment of patients with bronchiectasis in India. METHODS: The Indian bronchiectasis registry is a multicentre, prospective, observational cohort study. Adult patients ( 6518 years) with CT-confirmed bronchiectasis were enrolled from 31 centres across India. Patients with bronchiectasis due to cystic fibrosis or traction bronchiectasis associated with another respiratory disorder were excluded. Data were collected at baseline (recruitment) with follow-up visits taking place once per year. Comprehensive clinical data were collected through the European Multicentre Bronchiectasis Audit and Research Collaboration registry platform. Underlying aetiology of bronchiectasis, as well as treatment and risk factors for bronchiectasis were analysed in the Indian bronchiectasis registry. Comparisons of demographics were made with published European and US registries, and quality of care was benchmarked against the 2017 European Respiratory Society guidelines. FINDINGS: From June 1, 2015, to Sept 1, 2017, 2195 patients were enrolled. Marked differences were observed between India, Europe, and the USA. Patients in India were younger (median age 56 years [IQR 41-66] vs the European and US registries; p<0\ub70001]) and more likely to be men (1249 [56\ub79%] of 2195). Previous tuberculosis (780 [35\ub75%] of 2195) was the most frequent underlying cause of bronchiectasis and Pseudomonas aeruginosa was the most common organism in sputum culture (301 [13\ub77%]) in India. Risk factors for exacerbations included being of the male sex (adjusted incidence rate ratio 1\ub717, 95% CI 1\ub703-1\ub732; p=0\ub7015), P aeruginosa infection (1\ub729, 1\ub710-1\ub750; p=0\ub7001), a history of pulmonary tuberculosis (1\ub720, 1\ub707-1\ub734; p=0\ub7002), modified Medical Research Council Dyspnoea score (1\ub732, 1\ub725-1\ub739; p<0\ub70001), daily sputum production (1\ub716, 1\ub703-1\ub730; p=0\ub7013), and radiological severity of disease (1\ub703, 1\ub701-1\ub704; p<0\ub70001). Low adherence to guideline-recommended care was observed; only 388 patients were tested for allergic bronchopulmonary aspergillosis and 82 patients had been tested for immunoglobulins. INTERPRETATION: Patients with bronchiectasis in India have more severe disease and have distinct characteristics from those reported in other countries. This study provides a benchmark to improve quality of care for patients with bronchiectasis in India. FUNDING: EU/European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis Consortium, European Respiratory Society, and the British Lung Foundation

Inflation and Dark Energy from spectroscopy at z > 2

The expansion of the Universe is understood to have accelerated during two epochs: in its very first moments during a period of Inflation and much more recently, at z < 1, when Dark Energy is hypothesized to drive cosmic acceleration. The undiscovered mechanisms behind these two epochs represent some of the most important open problems in fundamental physics. The large cosmological volume at 2 < z < 5, together with the ability to efficiently target high-$z$ galaxies with known techniques, enables large gains in the study of Inflation and Dark Energy. A future spectroscopic survey can test the Gaussianity of the initial conditions up to a factor of ~50 better than our current bounds, crossing the crucial theoretical threshold of $\sigma(f_{NL}^{\rm local})$ of order unity that separates single field and multi-field models. Simultaneously, it can measure the fraction of Dark Energy at the percent level up to $z = 5$, thus serving as an unprecedented test of the standard model and opening up a tremendous discovery space

Astro2020 APC White Paper: The MegaMapper: a z &gt; 2 spectroscopic instrument for the study of Inflation and Dark Energy

MegaMapper is a proposed ground-based experiment to measure Inflation parameters and Dark Energy from galaxy redshifts at